HUTCHMED Announces Total Voting Rights as of April 30, 2026

HUTCHMED (China) Limited reported that as of April 30, 2026, the company's issued share capital consisted of 872,335,120 ordinary shares. Each share carries one voting right, and no shares are held in treasury. This figure serves as the denominator for shareholders calculating their disclosure obligations under the Financial Conduct Authority's rules. The total number of ordinary shares is equivalent to 872,335,120 depositary interests traded on AIM and 174,467,024 American depositary shares traded on Nasdaq, assuming full conversion. HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.